ChiCTR2200057778 版本V1.0 版本创建时间2022/03/17 18:29:04 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200057778 

最近更新日期:

Date of Last Refreshed on:

2022-03-17 18:27:01 

注册时间:

Date of Registration:

2022-03-17 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

紫苜蓿粉结合膳食健康教育对人体血脂异常的改善研究

Public title:

Improvement of alfalfa powder combined with dietary health education on human dyslipidemia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

紫苜蓿粉结合膳食健康教育对人体血脂异常的改善研究

Scientific title:

Improvement of alfalfa powder combined with dietary health education on human dyslipidemia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王沛 

研究负责人:

孙桂菊 

Applicant:

Pei Wang 

Study leader:

Guiju Sun 

申请注册联系人电话:

Applicant telephone:

15210904901

研究负责人电话:

Study leader's
telephone:

13951928860

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wangpei929@seu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

gjsun@seu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市鼓楼区东南大学丁家桥校区公卫学院

研究负责人通讯地址:

江苏省南京市鼓楼区东南大学丁家桥校区公卫学院

Applicant address:

Public Health College, dingjiaqiao campus, Southeast University, Gulou District, Nanjing, Jiangsu Province

Study leader's address:

Public Health College, dingjiaqiao campus, Southeast University, Gulou District, Nanjing, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

210003

研究负责人邮政编码:

Study leader's postcode:

210003

申请人所在单位:

东南大学

Applicant's institution:

Southeast University

研究负责人所在单位:

东南大学

Affiliation of the Leader:

Southeast University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

ChiECRCT20210324

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国临床注册实验伦理审查委员会

Name of the ethic committee:

China Ethics Committee of Registering Clinical Trials

伦理委员会批准日期:

Date of approved by ethic committee:

2021-08-04 00:00:00

伦理委员会联系人:

吴莼

Contact Name of the ethic committee:

Wu Chun

伦理委员会联系地址:

成都国学巷37号,四川大学华西医院行政楼八角亭2楼2092室

Contact Address of the ethic committee:

Room 2092, 2 / F, Bajiaoting, administration building, West China Hospital, Sichuan University, No. 37, Guoxue lane, Chengdu

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

东南大学

Primary sponsor:

Southeast University

研究实施负责(组长)单位地址:

江苏南京

Primary sponsor's address:

Southeast University

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

东南大学

具体地址:

鼓楼区丁家桥87号

Institution
hospital:

Southeast University

Address:

87 Dingjiaqiao Road, Gulou District

经费或物资来源:

东南大学、农业农村部食物与营养发展研究所、北京东方倍力营养科技有限公司

Source(s) of funding:

Southeast University, Institute of food and nutrition development of the Ministry of agriculture and rural areas, Beijing Billon Power Nutrition Technology Co., Ltd

研究疾病:

血脂异常  

Target disease:

Dyslipidemia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

研究紫苜蓿粉结合膳食教育对人体血脂异常的改善能力  

Objectives of Study:

To study the improvement ability of alfalfa powder combined with dietary education on human dyslipidemia

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.以下三个血脂指标至少满足一项。
胆固醇(TC):200-278mg/dL或5.2-7.2mmol/L
甘油三脂(TG):150-200mg/dL或1.7-2.3 mmol/L
低密度脂蛋白(LDL-C):130-188mg/dL或3.4-4.9 mmol/L
2.性别不限;
3.年龄≥18周岁;
4.血压正常(收缩压低于140mmHg,舒张压低于90mmHg);
5.近半年内未服用降血脂类药物。

Inclusion criteria

1.The following three blood lipid indexes (TC, TG, LDL-C) meet at least one.
Total Cholesterol(TC):200-278mg/dL or 5.2-7.2mmol/l
Triglyceride(TG):150-200mg/dL or 1.7-2.3mmol/L
Low density lipoprotein (LDL-C):130-188mg/dL or 3.4-4.9mmol/L
2.Unlimited gender;
3.Age≥18 years old;
4.Normal blood pressure (systolic blood pressure <140mmHg, diastolic blood pressure <90mmHg);
5.No hypolipidemic drugs have been taken in recent half a year.

排除标准:

1.近半年曾服用降血脂药物,影响到对结果的判断者;
2.糖尿病患者;
3.妊娠或哺乳期妇女;
4.伴有严重并发症,合并有心、脑、肝、肾和造血系统等严重疾病,精神病患者,行动不能自理者;
5.哮喘、嗜酒、甲亢患者、恶性肿瘤患者及接受激素治疗者等;
6.无法按规定食用受试样品,或资料不全,影响功效判断者;
7.正参加其它临床试验的患者;
8.研究人员认为其他原因不适合临床试验者。

Exclusion criteria:

1.Those who have taken hypolipidemic drugs for nearly half a year have affected the judgment of the results;
2.Diabetic patients;
3.Pregnant or lactating women;
4.Accompanied by serious complications, complicated with serious diseases such as heart, brain, liver, kidney and hematopoietic system, mentally ill patients and unable to take care of themselves;
5.Patients with asthma, alcoholism, hyperthyroidism, malignant tumors and those receiving hormone therapy;
6.Unable to eat the test sample as required, or the data is incomplete, which affects the judgment of efficacy;
7.Patients who are participating in other clinical trials;
8.The researchers believe that other reasons are not suitable for clinical trials.

研究实施时间:

Study execute time:

From 2022-04-08 00:00:00 To 2022-07-08 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-03-21 00:00:00 To 2022-04-05 00:00:00

干预措施:

Interventions:

组别:

1组

样本量:

80

Group:

Group 1

Sample size:

干预措施:

紫苜蓿营养粉+膳食健康教育

干预措施代码:

Intervention:

Alfalfa nutrition powder + dietary health education

Intervention code:

组别:

2组

样本量:

80

Group:

Group 2

Sample size:

干预措施:

膳食健康教育

干预措施代码:

Intervention:

Dietary health education

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河南 

市(区县):

鹤壁 

Country:

China

Province:

He'nan

City:

Hebi

单位(医院):

鹤壁市人民医院 

单位级别:

三级 

Institution
hospital:

Hebi People's Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

总胆固醇

指标类型:

主要指标

Outcome:

Total cholesterol

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总甘油三酯

指标类型:

主要指标

Outcome:

Total glyceride

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

低密度脂蛋白胆固醇

指标类型:

主要指标

Outcome:

Low density lipoprotein cholesterol

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

高密度脂蛋白胆固醇

指标类型:

主要指标

Outcome:

High density lipoprotein cholesterol

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

载脂蛋白A1

指标类型:

主要指标

Outcome:

Apolipoprotein A1

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

载脂蛋白B

指标类型:

主要指标

Outcome:

Apolipoprotein B

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脂蛋白a

指标类型:

主要指标

Outcome:

Lipoprotein a

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血糖

指标类型:

主要指标

Outcome:

Blood glucose

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

炎症因子

指标类型:

主要指标

Outcome:

Inflammatory factors

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脉搏波传导速度

指标类型:

主要指标

Outcome:

Pulse wave velocity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究者通过Excel生成随机数后建立随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

The researchers generated random numbers through Excel and established random sequences

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

not public

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

不公开

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

not public

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-03-17 18:27:01